Patterns of Performance of Retroperitoneal Lymph Node Dissections by American Urologists: Most Retroperitoneal Lymph Node Dissections in the United States Are Performed by Low-volume Surgeons
Authors:
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Higher surgeon and hospital volume improves long‐term survival after radical cystectomyCancer, 2013
- Hospital Surgical Volume, Utilization, Costs and Outcomes of Retroperitoneal Lymph Node Dissection for Testis CancerAdvances in Urology, 2012
- Adverse Prognostic Factors for Testicular Cancer–Specific Survival: A Population-Based Study of 27,948 PatientsJournal of Clinical Oncology, 2011
- Contemporary Lymph Node Counts During Primary Retroperitoneal Lymph Node DissectionUrology, 2011
- Evaluation of lymph node counts in primary retroperitoneal lymph node dissectionCancer, 2010
- The Total Number of Retroperitoneal Lymph Nodes Resected Impacts Clinical Outcome After Chemotherapy for Metastatic Testicular CancerUrology, 2010
- Randomized Phase III Trial Comparing Retroperitoneal Lymph Node Dissection With One Course of Bleomycin and Etoposide Plus Cisplatin Chemotherapy in the Adjuvant Treatment of Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: AUO Trial AH 01/94 by the German Testicular Cancer Study GroupJournal of Clinical Oncology, 2008
- Surgeon Volume and Operative Mortality in the United StatesNew England Journal of Medicine, 2003
- Impact of the Treating Institution on Survival of Patients With "Poor-Prognosis" Metastatic NonseminomaJNCI: Journal of the National Cancer Institute, 1999
- Management of malignant teratoma: does referral to a specialist unit matter?The Lancet, 1993